Rhabdomyosarcoma Pipeline Studied by Global Markets Direct in In-Demand Report Published at MarketPublishers.com
05 Aug 2013 • by Natalie Aster
LONDON – In 2011, the world rhabdomyosarcoma therapeutics market was estimated at just under USD 40 million. It is expected to demonstrate slow but sustainable growth at a CAGR of around 2.3% in the upcoming years, and it is predicted to surpass a USD 45.78 million mark by 2019.
The market for rhabdomyosarcoma therapeutics is characterized by weak competition, given the existence of only one approved drug, vincristine. The market presents untapped opportunities for firms having new approaches to rhabdomyosarcoma treatment.
In-demand research study “Rhabdomyosarcoma - Pipeline Review, H1 2013” worked out by Global Markets Direct describes the global therapeutic scenario for Rhabdomyosarcoma.
The report provides an extensive overview of the rhabdomyosarcoma therapeutic pipeline. It uncovers essential information on the most recent therapeutic developments, reviews latest updates in the field and discloses details on late-stage and discontinued projects. The research study offers data on key industry players, examines products under development, traces the latest activities related to the market, and analyzes the rhabdomyosarcoma pipeline by route of administration, molecule type, and monotherapy and combination products.
Rhabdomyosarcoma - Pipeline Review, H1 2013
Published: June, 2013
Price: US$ 2,000.00
More Topical Research Reports by Global Markets Direct Include:
- HIV / AIDS - Pipeline Review, H2 2013
- Astrocytoma - Pipeline Review, H2 2013
- Primary Dysmenorrhea - Pipeline Review, H2 2013
- Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2013
- Nausea - Pipeline Review, H2 2013
- Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2013
More market research reports by the publisher can be found at Global Markets Direct page.